Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Al Malki, M. M., London, K., Baez, J., Akahoshi, Y., Hogan, W. J., Etra, A., Choe, H., Hexner, E., Langston, A., Abhyankar, S., Ponce, D. M., DeFilipp, Z., Kitko, C. L., Adekola, K., Reshef, R., Ayuk, F., Capellini, A., Chanswangphuwana, C., Eder, M., … Levine, J. E. (2023). Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease. Blood Advances, 7(17), 5189–5198. https://doi.org/10.1182/bloodadvances.2023009853
Authors:
Monzr M. Al Malki
Kaitlyn London
Janna Baez
Yu Akahoshi
William J. Hogan
Aaron Etra
Hannah Choe
Elizabeth O. Hexner
Amelia Langston
Sunil Abhyankar
Doris M. Ponce
Zachariah DeFilipp
Carrie L. Kitko
Kehinde Adekola
Ran Reshef
Francis Ayuk
Alexandra Capellini
Chantiya Chanswangphuwana
Matthias Eder
Gilbert Eng
Isha Gandhi
Stephan A. Grupp
Sigrun Gleich
Ernst Holler
Nóra Rebeka Jávorniczky
Stelios Kasikis
Steven Kowalyk
George Morales
Umut Özbek
Wolf Rösler
Nikolaos Spyrou
Gregory A. Yanik
Rachel Young
Yi‐Bin Chen
Ryotaro Nakamura
James L.M. Ferrara
John E. Levine
Affiliated Authors:
Ran Reshef
Columbia Affiliation:
Subjects:
Graft vs Host Disease (MeSH)
Hematopoietic Stem Cell Transplantation (MeSH)
Hematopoietic Stem Cell Biology (OpenAlex Topic)
Natural Killer Cells in Immunity (OpenAlex Topic)
Regulatory T Cell Development and Function (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/bloodadvances.2023009853
PMID:
37235690
DOI:
10.1182/bloodadvances.2023009853
Journal:
Blood Advances
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record

Record Created: